Wei S, Li SM, An W, et al. - In this randomized, placebo-controlled, double-masked study, researchers tested the safety and effectiveness of atropine, 0.01%, eyedrops on slowing myopia progression and axial elongation in Chinese children. In total, 220 children, aged 6 to 12 years, with the myopia of −1.00 D to −6.00 D in both eyes were recruited between April 2018 and July 2018 at Beijing Tongren Hospital, Beijing, China. Study participants were randomly assigned in a 1:1 ratio to atropine, 0.01%, or placebo groups to be administered once nightly to both eyes for 1 year. The authors discovered that atropine, 0.01%, eyedrops decreased myopia progression and axial elongation relative to placebo treatment after 1 year. There were no serious atropine-related adverse events reported. Although the clinical significance of the outcomes can not be determined from this trial, these 1-year findings, limited by nearly 70% follow-up, indicate that atropine, 0.01%, eyedrops can delay the progression of myopia and axial elongation in children and warrant future research to evaluate longer-term outcomes and potential effects on slowing sight-threatening pathologic changes later in life.